Stock comparison
Alnylam Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALNY
Alnylam Pharmaceuticals
Market cap
$39.71B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALNY | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 75B | IDXX |
| Benjamin Graham | 80D | 80A | Tie |
| Philip Fisher | 79B | 75B | ALNY |
| Peter Lynch | 81A | 71B | ALNY |
| Joel Greenblatt | 63C | 83C | IDXX |
| Charlie Munger | 75D | 87A | IDXX |
| Terry Smith | 75B | 84A | IDXX |
Side-by-side metrics
| Metric | ALNY | IDXX |
|---|---|---|
| Market cap | $39.71B | $44.12B |
| P/E (TTM) | 66.1x | 39.0x |
| EV/EBIT | 75.5x | 31.6x |
| ROIC (TTM) | 19.66% | 40.66% |
| Gross margin | 80.89% | 62.05% |
| Net margin | 13.46% | 24.63% |
| Revenue CAGR 5y | 44.82% | 7.56% |
| EPS CAGR 5y | 38.42% | 10.79% |
| Debt / Equity | 1.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Revenue CAGR 5y44.82%vs 7.56%+83%
- EPS CAGR 5y38.42%vs 10.79%+72%
- Gross margin80.89%vs 62.05%+23%
IDXX leads on
- EV/EBIT31.6xvs 75.5x+58%
- ROIC (TTM)40.66%vs 19.66%+52%
- Net margin24.63%vs 13.46%+45%
- Debt / Equity0.7xvs 1.2x+41%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.